Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.

Masson W, Lobo M, Nogueira JP, Barbagelata L, Touzas P, Frías JP

Reviews in endocrine & metabolic disorders1 Oct 2025Cited by 6 (Europe PMC)

PMID41032183DOI10.1007/s11154-025-09991-4PepBankPUB-41032183

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis, tirzepatide reduced hsCRP compared with placebo (MD -32.9).
In plain wordsIn pooled studies, tirzepatide lowered the inflammation marker hsCRP more than placebo.
Peptide
Tirzepatide
Outcome
DecreasehsCRP versus placebo (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
MD
−32.9 % change
hsCRP
Source sentences
Summary
Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: -32.9; 95% confidence interval [CI]: -33.6 to - 32.2; I²=15.3%) and IL-6 (MD: -17.8; 95% CI: -24.3 to - 11.3; I² = 1.6%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218301
02HumanSystematic reviewEfficacy outcome
In a meta-analysis, tirzepatide reduced IL-6 compared with placebo (MD -17.8).
In plain wordsIn pooled studies, tirzepatide lowered the inflammation marker IL-6 more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseIL-6 versus placebo (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
MD
−17.8 % change
IL-6
Source sentences
Summary
Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: -32.9; 95% confidence interval [CI]: -33.6 to - 32.2; I²=15.3%) and IL-6 (MD: -17.8; 95% CI: -24.3 to - 11.3; I² = 1.6%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218302
03HumanSystematic reviewEfficacy outcome
In a meta-analysis, hsCRP was significantly reduced with tirzepatide 15 mg (MD -32.9).
In plain wordsIn pooled studies, tirzepatide 15 mg lowered the inflammation marker hsCRP.
Peptide
Tirzepatide
Outcome
DecreasehsCRP at tirzepatide 15 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 mgAs given in this study (human).
Measurements
MD
−32.9 % change
hsCRP, 15 mg
Source sentences
Summary
at 15 mg (MD: -32.9; 95% CI: -33.6 to - 32.2; I²=4.4%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218303
04HumanSystematic reviewEfficacy outcome
In a meta-analysis, hsCRP was significantly reduced with tirzepatide 10 mg (MD -33.9).
In plain wordsIn pooled studies, tirzepatide 10 mg lowered the inflammation marker hsCRP.
Peptide
Tirzepatide
Outcome
DecreasehsCRP at tirzepatide 10 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 mgAs given in this study (human).
Measurements
MD
−33.9 % change
hsCRP, 10 mg
Source sentences
Summary
10 mg (MD: -33.9; 95% CI: -50.3 to - 17.6; I²=41.8%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218304
05HumanSystematic reviewEfficacy outcome
In a meta-analysis, hsCRP was significantly reduced with tirzepatide 5 mg (MD -20.3).
In plain wordsIn pooled studies, tirzepatide 5 mg lowered the inflammation marker hsCRP.
Peptide
Tirzepatide
Outcome
DecreasehsCRP at tirzepatide 5 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 mgAs given in this study (human).
Measurements
MD
−20.3 % change
hsCRP, 5 mg
Source sentences
Summary
and 5 mg (MD: -20.3; 95% CI: -35.2 to - 5.3; I²=0%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218305
06HumanSystematic reviewEfficacy outcome
In a meta-analysis, IL-6 was significantly reduced with tirzepatide 5 mg (MD -18.8).
In plain wordsIn pooled studies, tirzepatide 5 mg lowered the inflammation marker IL-6.
Peptide
Tirzepatide
Outcome
DecreaseIL-6 at tirzepatide 5 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 mgAs given in this study (human).
Measurements
MD
−18.8 % change
IL-6, 5 mg
Source sentences
Summary
at 5 mg (MD: -18.8; 95% CI: -32.9 to - 4.6; I²=17.2%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218306
07HumanSystematic reviewEfficacy outcome
In a meta-analysis, IL-6 was significantly reduced with tirzepatide 10 mg (MD -17.9).
In plain wordsIn pooled studies, tirzepatide 10 mg lowered the inflammation marker IL-6.
Peptide
Tirzepatide
Outcome
DecreaseIL-6 at tirzepatide 10 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
10 mgAs given in this study (human).
Measurements
MD
−17.9 % change
IL-6, 10 mg
Source sentences
Summary
10 mg (MD: -17.9; 95% CI: -28.2 to - 7.7; I²=2.1%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218307
08HumanSystematic reviewEfficacy outcome
In a meta-analysis, IL-6 was significantly reduced with tirzepatide 15 mg (MD -16.8).
In plain wordsIn pooled studies, tirzepatide 15 mg lowered the inflammation marker IL-6.
Peptide
Tirzepatide
Outcome
DecreaseIL-6 at tirzepatide 15 mg
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
15 mgAs given in this study (human).
Measurements
MD
−16.8 % change
IL-6, 15 mg
Source sentences
Summary
and 15 mg (MD: -16.8; 95% CI: -31.1 to - 2.6; I²=47.4%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6).
Summary · context
Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis).
Report a problemFND-4103218308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.